Axsome Therapeutics, Inc. Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
Axsome Therapeutics, Inc. announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD Phase 3... | November 29, 2022
Alzheimer Disease Cooperative Study Axsome Therapeutics Inc Drug Administration Axsome Therapeutics Assessing Clinical Outcomes Disease Agitation
Source: marketscreener.com